Implementing the Sharps Regulations in the NHS
Over a year since measures were introduced to curb the risk of sharps injuries, feedback from some NHS Trusts, in terms of the legislation, indicates that confusion and ignorance still exists, and much work is still to be carried out (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 8, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
Patient safety and analysis of errors
This article provides an overview on the techniques of error analysis, how to draw conclusions from these analyses and how to prevent medication errors in the future (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 8, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
Imagination, skills and organisation
More than 3500 attendees from 35 countries gathered in Barcelona for the 19th congress of the European Association of Hospital Pharmacists in March 2014. The main theme was the innovative hospital pharmacist (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 8, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
Oral anticoagulants: the dawning of a brighter era
Experts came together at a Bayer-sponsored satellite symposium at the 2014 European Association of Hospital Pharmacists conference in Barcelona, Spain to discuss the future of direct oral anticoagulants (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 8, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
Progress in the treatment of early-stage inflammatory joint disease
Pfizer has announced that the European Commission has granted a licence extension for Enbrel (etanercept) in the treatment of adult patients with severe non-radiographic axial spondyloarthritis. (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 6, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Rheumatology early-stage inflammatory joint disease enbrel etanercept Featured Articles pfizer Source Type: news
Eliquis receives EU approval
Bristol-Myers Squibb Company and Pfizer Inc. have announced that the European Commission has approved Eliquis for the treatment of deep vein thrombosis and pulmonary embolism, and the prevention of recurrent DVT and PE in adults. (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 6, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Anti-coagulants Haematology Bristol-Myers Squibb Company dvt Eliquis EU approval Latest News pe Pfizer Inc. Source Type: news
European Association of Faculties of Pharmacy elections
The General Assembly of European Association of Faculties of Pharmacy recently elected two new members for its Executive Committee. (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 4, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick European Conferences and Symposia EAFP European Association of Faculties of Pharmacy general meeting Latest News Source Type: news
Altacor growth ‘to accelerate’
Esperante, the private, Netherlands-based life science investment company, has announced it has completed the acquisition of Altacor. (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 4, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Industry News Altacor Limited Esperante Latest News life science investment ophthalmology Source Type: news
People in Ireland innovative cancer treatment access
Takeda Products Ireland Ltd has announced that Adcetris (brentuximab vedotin) is now available for use in Ireland for the treatment of patients with Hodgkin lymphoma. (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 31, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Oncology Adcetris brentuximab vedotin HL Hodgkin lymphoma ireland Latest News National Cancer Control Programme (NCCP) Oncology Drug Management System Takeda Products Ireland Ltd Source Type: news
Vipidia™, fixed-dose combinations Vipdomet™ and Incresync™ label updates
Takeda Pharmaceuticals International GmbH ('Takeda') has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued positive opinions for updates to the Summary of Product Characteristics (SmPC) for Vipidia™ (alogliptin) and the fixed-dose combination (FDC) therapies Vipdomet™ (alogliptin and metformin) and Incresync™ (alogliptin and pioglitazone). (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 29, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Diabetes Latest News Source Type: news
Positive CHMP opinions for label updates to Vipidia™ and fixed-dose combinations Vipdomet™ and Incresync™
Takeda Pharmaceuticals International GmbH ('Takeda') has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued positive opinions for updates to the Summary of Product Characteristics (SmPC) for Vipidia™ (alogliptin) and the fixed-dose combination (FDC) therapies Vipdomet™ (alogliptin and metformin) and Incresync™ (alogliptin and pioglitazone). (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 29, 2014 Category: Drugs & Pharmacology Authors: ebercott Tags: *** Editor's Pick Diabetes Latest News Source Type: news
CHMP positive opinion for Xultophy?
Novo Nordisk today announced that the Committee for Medicinal Products for Human Use under the European Medicines Agency has adopted a positive opinion for Xultophy, the first-ever once-daily basal insulin (insulin degludec, Tresiba)
and GLP-1 analogue (liraglutide, Victoza) in one pen. (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 28, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Diabetes Featured Articles Tresiba Xultophy Source Type: news
NIHR clinical research network GCP training hits new high
Almost 23,000 healthcare professionals undertook the National Institute for Health Research Clinical Research Network’s Good Clinical Practice training during 2013–14, latest figures reveal. (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 24, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Industry News Guidelines good clinical practice Latest News medicines and healthcare products regulatory agency mhra national institute for health research NIHR Source Type: news
Heart patients in England and Wales offered more treatment choice
Revised guidance from the National Institute for Health and Care Excellence, recommends once-daily, oral antiplatelet prasugrel (Efient®), in combination with aspirin, as a cost-effective option compared with generic clopidogrel, for a wider group of acute coronary syndrome patients having primary or delayed percutaneous coronary intervention. (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 24, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Cardiovascular medicine acs acute coronary syndrome aspirin clopidogrel Efient® Latest News National Institute for Health and Care Excellence pci percutaneous coronary intervention prasugrel Source Type: news
International Society of Paediatric Oncology 46th Congress
The Congress of the International Society of Paediatric Oncology (SIOP 2014) will bring together worldwide experts in paediatric oncology. Learn from our top-notch faculty in symposia, lectures and in special sessions for each of our different programmes. (Source: Pharmacy Europe)
Source: Pharmacy Europe - July 17, 2014 Category: Drugs & Pharmacology Authors: AMcculloch Tags: *** Editor's Pick Other conferences & symposia International Society of Paediatric Oncology Latest News SIOP Source Type: news
